Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of the LIVESTRONG at the YMCA Exercise Program on Cancer Related Outcomes in Cancer Survivors

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Yale University
Sponsor:
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT02112149
First received: April 9, 2014
Last updated: April 10, 2014
Last verified: April 2014
  Purpose

The proposed study is a randomized trial evaluating the impact of the 12-week LIVESTRONG exercise program vs. waitlist control on cancer-related outcomes in 200 cancer survivors.


Condition Intervention Phase
Breast Cancer
Behavioral: LIVESTRONG
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Effect of the LIVESTRONG at the YMCA Exercise Program on Cancer Related Outcomes in Cancer Survivors

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Change in Physical Activity Level [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Modifiable Physical Activity Questionnaire will be used to assess physical activity levels at baseline and 3-months to examine whether the LIVESTRONG program led to maintenance or further increases in physical activity levels compared with participants randomized to control.


Secondary Outcome Measures:
  • Change in Body Fat Percentage [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Dual-energy X-ray absorptiometry (DEXA) scans will be used to assess body fat percentage, lean body mass, and bone mineral density at baseline and 3-months. Study participants will receive a copy of their 3-month DEXA report.

  • Change in Lean Body Mass [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Dual-energy X-ray absorptiometry (DEXA) scans will be used to assess body fat percentage, lean body mass, and bone mineral density at baseline and 3-months. Study participants will receive a copy of their 3-month DEXA report.

  • Change in Bone Mineral Density [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Dual-energy X-ray absorptiometry (DEXA) scans will be used to assess body fat percentage, lean body mass, and bone mineral density at baseline and 3-months. Study participants will receive a copy of their 3-month DEXA report.

  • Change in Body Mass Index (BMI) [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Height and weight will be measured at baseline and 3-months. Participants will be weighed in light indoor clothing, without shoes, rounding up to the nearest 0.1 kg; height will be measured without shoes, using a stadiometer, rounding up to the nearest 0.1 cm. BMI will be calculated using the formula: kg/m2. All measures will be performed and recorded twice in succession.

  • Change in Blood Biomarkers [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Fasting blood (> 12 hours) will be collected at baseline and 12 weeks for measurement of insulin, c-reactive protein, leptin and adiponectin, which are biomarkers that have been linked to cancer prognosis in prior studies.


Other Outcome Measures:
  • Change in Walk Distance [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    All participants will undergo a 6MWT at baseline and after the 12-week protocol period. Participants will wear tennis shoes and will walk indoors along a long, flat, straight, enclosed corridor, on a flat surface for 6 minutes. They will be instructed to walk continuously along an area at least 50 feet in length, back and forth, for 6 minutes.

  • Change in Quality of Life [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Quality of Life (QOL) will be measured using the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire (version 3) as well as the PROMISE Q. Breast cancer survivors will also complete the FACT-B-ES form that assesses endocrine-related symptoms specific to breast cancer. Additionally, fatigue will be assessed through the FACT-Fatigue Scale, which consists of 13 items designed to assess fatigue in terms of its intensity and interference with performing everyday functions.

  • Lymphedema Questionnaire [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Breast cancer survivors will complete a validated Norman Lymphedema Questionnaire. Previous methodologically strong studies have shown exercise, including upper body resistance/strength training, to decrease the risk of exacerbation of lymphedema as well as severity of lymphedema symptoms in breast cancer survivors randomized to a twice-weekly year long strength training program compared with breast cancer survivors randomized to control. Given these findings, breast cancer survivors with lymphedema will not be excluded from participation in the study. However, MD consent to exercise will be obtained from her oncologist.

  • Change in Breast Cancer Prevention Trial Symptom Checklist [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    The Breast Cancer Prevention Trial Symptom Checklist Short Form is a symptom checklist that will be completed by all study participants at baseline and 3-months to assess side effects/symptoms related to cancer surgery and treatment and how exercise may improve or prevent some of these symptoms. Symptoms such as lymphedema, neuropathy, and arthralgias will be assessed.


Estimated Enrollment: 200
Study Start Date: February 2013
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LIVESTRONG Program
Participants randomized to the LIVESTRONG exercise program will attend a 12-week LIVESTRONG Program at one of the participating YMCA's in the greater Boston area or CT. We will have monthly teleconferences to discuss the study, recruitment, and the exercise program. Lastly, throughout the 12-week program, participants will record their attendance at the LIVESTRONG program as well as any exercise done outside of the program. We will provide them with a Physical Activity Log book to record their exercise.
Behavioral: LIVESTRONG
The LIVESTRONG at the YMCA is a twelve-week, small group (< 16 participants) program designed for adult cancer survivors. YMCA fitness instructors work with each participant to fit the program to their individual needs. The instructors are trained in the elements of cancer, post rehabilitation exercise and supportive cancer care. There are two YMCA fitness instructors overseeing each exercise session. Each session is 90 min in duration, twice per week, for 12-wks (total of 24 sessions). Each session begins with a warm-up, then aerobic exercise (e.g., treadmill) and resistance training exercises, followed by a cool-down period, and follows the recommendations of the American College of Sports Medicine.
No Intervention: Wait-List Control
Baseline data will be collected from all study participants before randomization. If a participant is randomized to wait-list control, then he/she will be told that he/she will start the LIVESTRONG program after three months and after he/she returns to Yale or DFCI to complete the 3-month clinic visit.

Detailed Description:

The proposed study is a randomized trial evaluating the impact of the 12-week LIVESTRONG exercise program vs. waitlist control on cancer-related outcomes in 200 cancer survivors. Participants will undergo baseline testing at Dana-Farber or Yale, including administration of questionnaires to assess quality of life and the presence of cancer and treatment-related symptoms, fasting blood draw, and evaluation of body composition (using dual energy X-ray absorptiometry (DEXA). Participants will then take part in the 12-week LIVESTRONG Program or will be assigned to a wait-list control group. All measurements will be repeated at Dana-Farber or Yale after the 12-week exercise program or control period.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cancer diagnosis excluding non-melanoma skin cancer
  • Physically able to exercise
  • Able to complete forms and understand instructions in English
  • Agrees to be randomly assigned to either exercise or wait-list control group
  • Willing and able to attend one of the LIVESTRONG at the YMCA programs for 12 weeks
  • Willing and able to complete the baseline and 3-month clinic visits

Exclusion Criteria:

  • > 80 years of age
  • < 18 years of age
  • Recent (past 6 months) stroke/myocardial infarction or congestive heart failure/documented ejection fraction < 40%
  • Plans to undergo a major surgical procedure in the next 6 months
  • Presence of dementia or major psychiatric disease that would preclude participation in a group-based exercise program
  • Pregnant women or women intending to become pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02112149

Contacts
Contact: Melinda L Irwin, P 203-785-6392 Melinda.irwin@yale.edu

Locations
United States, Connecticut
Yale University Recruiting
New Haven, Connecticut, United States, 06519
Contact: Melinda L Irwin, PhD, MPH    203-785-6392    Melinda.irwin@yale.edu   
Principal Investigator: Melinda L Irwin, PhD, MPH         
United States, Massachusetts
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Jennifer A Ligibel, MD    617-632-2175      
Principal Investigator: Jennifer A Ligibel, MD         
Sponsors and Collaborators
Yale University
Investigators
Principal Investigator: Melinda L Irwin, PhD, MPH Yale University
Principal Investigator: Jennifer A Ligibel, MD Dana-Farber Cancer Institute
  More Information

No publications provided

Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT02112149     History of Changes
Other Study ID Numbers: 1301011291
Study First Received: April 9, 2014
Last Updated: April 10, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Yale University:
Body Composition
Exercise
Survivorship

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases

ClinicalTrials.gov processed this record on November 20, 2014